Abstract:BACKGROUND:Despite recent reforms, distorting funding mechanisms and over-prescribing still maintain severe financial barriers to medicines access in China. Complicated and interrelated problems in the pharmaceutical sector require a common framework to be resolved as fragmented solutions do not work. We present a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and propose policy recommendations for promoting universal access to medicines in China.METHODS:Drawing on multiple sources of information, including a review of published literatures and official national data, field investigations in six provinces and interviews with key opinion leaders, this paper presents a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and proposes policy recommendations for promoting universal access to medicines in China.RESULTS:Public expenditure on medicines has been strictly controlled since the national healthcare reforms of 2009. Yet total pharmaceutical expenditure (TPE) and total health expenditure growth rates continuously outpaced the growth of gross domestic product (GDP). With 2.4% of GDP, TPE now exceeds that of most high income countries. The distorted provider and consumer incentives in the Chinese health system have not fundamentally changed. Price-setting and reimbursement mechanisms do not promote cost-effective use of medicines. Inappropriate price controls and perverse financial incentives are the un-resolved root causes of preference of originator brands for some major diseases and shortages of low-cost and low-consumption medicines. In addition, access to expensive life-saving medicines is yet systematically addressed.CONCLUSIONS:The complicated and interdependent problems interact in a way that leads to significant system problems in China, which create dual challenges that both the developing country and the developed countries are facing. To further promote access to medicines, China should speed up the re-assessment of the quality and efficacy of domestically produced generic medicines; coordinate various reforms of price determination, insurance payments, and procurement policies; address medicine shortages through comprehensive policies and legislation; establish specific mechanisms to achieve sustainable equitable access to expensive essential medicines with health technology assessment as a tool to ensure that policy and priority setting are created in a coherent and evidence-based way.

Governance Reforms in China's Essential Medicines System

An Analysis of China's National Essential Medicines Policy

Essential medicines system reform in China:Achievements and challenges

Health system reforms in China a half century apart: Continuity but adaptation

Health System Reform in Rural China: Voices of Healthworkers and Service-Users.

Health reform in China: Developments and future prospects

Health in China. the Healthcare Market.

Exploration and Consideration of Essential Medicine Supply Guarantee Reform in Poverty and Remote Areas of China: Based on Perspective of Supply Chain Governance

Investigation on the Difficulties of Implementation of National Essential Drug System

A Review of Promoting Access to Medicines in China - Problems and Recommendations.

Early appraisal of China's huge and complex health-care reforms

Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020

Introduction to Good Governance in US Drug Safety System Reform and its Enlightenment.

Reasons behind stymied public hospital governance reform in China.

China's Health Reform Update

Chinese-style Decentralization and Health System Reform.

Bureaucratic Marketization and Reforms of Public Hospitals in China

Moving Towards a Better Path? A Mixed-Method Examination of China's Reforms to Remedy Medical Corruption from Pharmaceutical Firms.

Problems and Reform Strategies of Medicines Distribution System in China

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

Milestones in China's Public Hospital Reform and an Insight Based on Corporate Governance Theories